Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Improved survival among hospitalized patients with COVID-19 treated with remdesivir and dexamethasone. A nationwide population-based cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{2274766b696c4f5190614353879b8ba2,
title = "Improved survival among hospitalized patients with COVID-19 treated with remdesivir and dexamethasone. A nationwide population-based cohort study",
abstract = "BACKGROUND: There is limited data on outcomes of moderate to severe Coronavirus disease 2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real-world setting.OBJECTIVE: To compare the effectiveness of standard of care (SOC) alone vs SOC plus remdesivir and dexamethasone.METHODS: Two population-based nationwide cohorts of individuals hospitalized with COVID-19 during February through December 2020. Death within 30 days and need of mechanical ventilation (MV) were compared by inverse probability of treatment weighted (ITPW) logistic regression analysis and shown as odds ratio (OR) with 95% confidence interval (CI).RESULTS: The 30-d mortality rate of 1694 individuals treated with remdesivir and dexamethasone in addition to SOC was 12.6% compared to 19.7% for 1053 individuals receiving SOC alone. This corresponded to a weighted OR of 30-day mortality of 0.47 (95% CI, 0.38-0.57) for patients treated with remdesivir and dexamethasone compared to patients receiving SOC alone. Similarly, progression to MV was reduced (OR 0.36 (95% CI, 0.29-0.46)).CONCLUSIONS AND RELEVANCE: Treatment of moderate to severe COVID-19 during June through December that included remdesivir and dexamethasone was associated with reduced 30-day mortality and need of MV compared to treatment in February through May.",
author = "Thomas Benfield and Jacob Bodilsen and Christian Brieghel and Harboe, {Zitta Barrella} and Marie Helleberg and Claire Holm and Israelsen, {Simone Bastrup} and Janne Jensen and Jensen, {Tomas {\O}stergaard} and Johansen, {Isik Somuncu} and Stine Johnsen and Madsen, {Birgitte Lindegaard} and Jens Lundgren and Meyer, {Christian Niels} and Rajesh Mohey and Pedersen, {Lars M{\o}ller} and Henrik Nielsen and Nielsen, {Stig L{\o}nberg} and Niels Obel and Omland, {Lars Haukali} and Daria Podlekareva and Poulsen, {Birgitte Klindt} and Pernille Ravn and Haakon Sandholdt and Jonathan Starling and Merete Storgaard and Christian S{\o}borg and S{\o}gaard, {Ole Schmeltz} and Torben Tranborg and Lothar Wiese and Christensen, {Hanne Rolighed}",
note = "{\textcopyright} The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.",
year = "2021",
month = jun,
day = "10",
doi = "10.1093/cid/ciab536",
language = "English",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "University of Chicago Press",

}

RIS

TY - JOUR

T1 - Improved survival among hospitalized patients with COVID-19 treated with remdesivir and dexamethasone. A nationwide population-based cohort study

AU - Benfield, Thomas

AU - Bodilsen, Jacob

AU - Brieghel, Christian

AU - Harboe, Zitta Barrella

AU - Helleberg, Marie

AU - Holm, Claire

AU - Israelsen, Simone Bastrup

AU - Jensen, Janne

AU - Jensen, Tomas Østergaard

AU - Johansen, Isik Somuncu

AU - Johnsen, Stine

AU - Madsen, Birgitte Lindegaard

AU - Lundgren, Jens

AU - Meyer, Christian Niels

AU - Mohey, Rajesh

AU - Pedersen, Lars Møller

AU - Nielsen, Henrik

AU - Nielsen, Stig Lønberg

AU - Obel, Niels

AU - Omland, Lars Haukali

AU - Podlekareva, Daria

AU - Poulsen, Birgitte Klindt

AU - Ravn, Pernille

AU - Sandholdt, Haakon

AU - Starling, Jonathan

AU - Storgaard, Merete

AU - Søborg, Christian

AU - Søgaard, Ole Schmeltz

AU - Tranborg, Torben

AU - Wiese, Lothar

AU - Christensen, Hanne Rolighed

N1 - © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

PY - 2021/6/10

Y1 - 2021/6/10

N2 - BACKGROUND: There is limited data on outcomes of moderate to severe Coronavirus disease 2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real-world setting.OBJECTIVE: To compare the effectiveness of standard of care (SOC) alone vs SOC plus remdesivir and dexamethasone.METHODS: Two population-based nationwide cohorts of individuals hospitalized with COVID-19 during February through December 2020. Death within 30 days and need of mechanical ventilation (MV) were compared by inverse probability of treatment weighted (ITPW) logistic regression analysis and shown as odds ratio (OR) with 95% confidence interval (CI).RESULTS: The 30-d mortality rate of 1694 individuals treated with remdesivir and dexamethasone in addition to SOC was 12.6% compared to 19.7% for 1053 individuals receiving SOC alone. This corresponded to a weighted OR of 30-day mortality of 0.47 (95% CI, 0.38-0.57) for patients treated with remdesivir and dexamethasone compared to patients receiving SOC alone. Similarly, progression to MV was reduced (OR 0.36 (95% CI, 0.29-0.46)).CONCLUSIONS AND RELEVANCE: Treatment of moderate to severe COVID-19 during June through December that included remdesivir and dexamethasone was associated with reduced 30-day mortality and need of MV compared to treatment in February through May.

AB - BACKGROUND: There is limited data on outcomes of moderate to severe Coronavirus disease 2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real-world setting.OBJECTIVE: To compare the effectiveness of standard of care (SOC) alone vs SOC plus remdesivir and dexamethasone.METHODS: Two population-based nationwide cohorts of individuals hospitalized with COVID-19 during February through December 2020. Death within 30 days and need of mechanical ventilation (MV) were compared by inverse probability of treatment weighted (ITPW) logistic regression analysis and shown as odds ratio (OR) with 95% confidence interval (CI).RESULTS: The 30-d mortality rate of 1694 individuals treated with remdesivir and dexamethasone in addition to SOC was 12.6% compared to 19.7% for 1053 individuals receiving SOC alone. This corresponded to a weighted OR of 30-day mortality of 0.47 (95% CI, 0.38-0.57) for patients treated with remdesivir and dexamethasone compared to patients receiving SOC alone. Similarly, progression to MV was reduced (OR 0.36 (95% CI, 0.29-0.46)).CONCLUSIONS AND RELEVANCE: Treatment of moderate to severe COVID-19 during June through December that included remdesivir and dexamethasone was associated with reduced 30-day mortality and need of MV compared to treatment in February through May.

U2 - 10.1093/cid/ciab536

DO - 10.1093/cid/ciab536

M3 - Journal article

C2 - 34111274

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

ER -

ID: 66133261